Anti-tumor pharmaceutical composition comprising azvudine

Abstract

The present invention discloses a pharmaceutical composition comprising azvudine and an EGFR/TKI inhibitor. The pharmaceutical composition of the present invention shows a good synergistic effect in antitumor, and can delay the generation of drug resistance and improve the therapeutic effect and safety, thereby achieving the goal of prolonging the survival of patients.

The invention claimed is: 
     
       1. A pharmaceutical composition, comprising:
 (i) azvudine or a pharmaceutically acceptable salt, or a stereoisomer thereof; 
 (ii) an EGFR/TKI inhibitor. 
 
     
     
       2. The pharmaceutical composition according to  claim 1 , wherein, the EGFR/TKI inhibitor is selected from the group consisting of osimertinib, gefitinib, erlotinib, doxitinib, olmutinib, icotinib, pyrotinib, dacomitinib, afatinib, neratinib, lapatinib, ABT-414, varlitinib, HLX-07, tesevatinib, theliatinib, epaltinib succinate, S-222611, furmonertinib, befotertinib, rezivertinib, poziotinib and a combination thereof. 
     
     
       3. The pharmaceutical composition according to  claim 1 , wherein the EGFR/TKI inhibitor is selected from the group consisting of osimertinib, doxitinib and a combination thereof. 
     
     
       4. The pharmaceutical composition according to  claim 1 , wherein the (i) and (ii) are administered simultaneously, separately, or sequentially, or the (i) and (ii) exist in the same dosage form.